Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases.

Goldfinch Biopharma Inc. (Cambridge, Mass.) CEO Tony Johnson told BioCentury that after

Read the full 444 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE